Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.


News

Open Targets consortium welcomes Genentech as newest member

14 November 2022

Open Targets announced today that Genentech, a member of the Roche Group, has joined the consortium, which identifies, prioritises, and validates drug targets to accelerate the development of safe and effective medicines. The second company to join the industry-academic partnership this year, Genentech will collaborate with other consortium members including EMBL’s European Bioinformatics Institute (EMBL-EBI), the Wellcome Sanger Institute, GSK, Bristol Myers Squibb, Sanofi, and Pfizer.

Read more


Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.


Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data


Follow Us


How Open Targets is using Artificial Intelligence and Machine Learning to identify and prioritise drug targets

Helena Cornu

2 December 2022

Open Targets Platform 22.11 has been released!

Sir Target

24 November 2022

Open Targets Genetics: version 8 is out!

Sir Target

13 October 2022

Open Targets Platform 22.09 has been released

Sir Target

3 October 2022

Open Targets Platform 22.06 has been released!

Sir Target

24 June 2022

Next steps in our web applications' architecture

Carlos Cruz

21 June 2022

How Lorenzo Bomba is using rare genetic variants to understand blood metabolites

Helena Cornu

31 May 2022

Open Targets Platform 22.04 has been released!

Sir Target

28 April 2022

How we overhauled our literature processing pipeline using Named Entity Recognition

Miguel Carmona, Helena Cornu

19 April 2022

Open Targets Platform 22.02 has been released!

Sir Target

1 March 2022

Open Targets Genetics: version 7 is out!

Sir Target

25 February 2022

How Nuria Lopez-Bigas is untangling the genetics of cancer

Helena Cornu

4 February 2022

Untangling the genetics of neuroinflammation: an interview with Yixi Chen

Helena Cornu

14 December 2021

Open Targets Platform 21.11 has been released!

Sir Target

29 November 2021

Open Targets Genetics: Version 6 is out!

Sir Target

25 November 2021

From genomes to medicines: an interview with Ian Dunham

Helena Cornu

14 October 2021

Open Targets Platform 21.09 has been released!

Sir Target

30 September 2021

Off the beaten path: combining genetic and small molecule approaches to validate novel drug targets

Helena Cornu

16 September 2021

David Gray of the Dundee Drug Discovery Unit shares three key pieces of advice from his career, through the story of the PCLX-001 molecule.

Building the eQTL Catalogue: a Q&A with Kaur Alasoo

Helena Cornu

7 September 2021

Kaur Alasoo explains how the eQTL Catalogue came together, and what their future plans are. The eQTL Catalogue is the largest compendium of uniformly processed eQTL summary statistics and fine-mapping results.

Summer School: A Crash Course in Open Targets, Part 3

Clare West

3 August 2021

Clare West navigates the data downloads for the Open Targets Platform and Genetics portal, showing you how to access and query the data using Spark.